文献速递外周动脉疾病

依度沙班联合阿司匹林与双联抗血小板治疗在外周动脉疾病患者血管内治疗中的对比:ePAD试验结果

Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial.
PubMed 文献 · J Endovasc Ther · 2018-01-01

ePAD随机试验纳入203例股腘动脉血管内治疗患者,比较阿司匹林联合依度沙班与阿司匹林联合氯吡格雷治疗3个月的安全性和疗效。结果显示两组大出血和危及生命出血风险无统计学差异,依度沙班组再狭窄/再闭塞发生率数值上较低但无统计学差异,需足够样本量试验证实。

要点

  • 依度沙班组无大出血或危及生命出血事件,氯吡格雷组按TIMI标准有2例大出血和2例危及生命出血。
  • 按ISTH标准,依度沙班组1例大出血和1例危及生命出血 vs 氯吡格雷组5例大出血和2例危及生命出血(RR 0.20,95%CI 0.02-1.70)。
  • 6个月观察,依度沙班组再狭窄/再闭塞发生率30.9% vs 氯吡格雷组34.7%(RR 0.89,95%CI 0.59-1.34,p=0.643)。

核心结论

  • 接受血管内治疗的患者使用依度沙班联合阿司匹林与氯吡格雷联合阿司匹林相比,大出血和危及生命出血事件风险相似。
  • 再狭窄/再闭塞事件发生率无统计学差异,但依度沙班联合阿司匹林组较低,需足够样本量试验证实。

研究设计与样本

  • 随机研究,2012年2月至2014年6月纳入203例接受股腘动脉血管内治疗的患者。
  • 随机分配101例(平均年龄68.0±10.4岁;67例男性)至依度沙班组,102例(平均年龄66.7±8.6岁;78例男性)至氯吡格雷组。
  • 两组分别接受阿司匹林联合依度沙班或阿司匹林联合氯吡格雷治疗3个月。

主要发现

  • 依度沙班组无大出血或危及生命出血事件;氯吡格雷组按TIMI标准有2例大出血和2例危及生命出血事件。
  • 按ISTH标准,依度沙班组1例大出血和1例危及生命出血事件 vs 氯吡格雷组5例大出血和2例危及生命出血事件(RR 0.20,95%CI 0.02-1.70)。
  • 按TIMI或ISTH标准评估,两种治疗的出血风险均无统计学差异。
  • 6个月观察后,依度沙班组再狭窄/再闭塞发生率30.9% vs 氯吡格雷组34.7%(RR 0.89,95%CI 0.59-1.34,p=0.643)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出需要足够样本量的试验来证实这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report a randomized study that investigated the safety (risk of major bleeds) and potential efficacy of edoxaban, an oral anticoagulant that targets the major components of arterial thrombi, to prevent loss of patency following endovascular treatment (EVT). METHODS: Between February 2012 and June 2014, 203 patients who underwent femoropopliteal EVT were randomized to receive aspirin plus edoxaban or aspirin plus clopidogrel for 3 months in the Edoxaban in Peripheral Arterial Disease (ePAD) study ( ClinicalTrials.gov identifier NCT01802775). Randomization assigned 101 patients (mean age 68.0±10.4 years; 67 men) to the edoxaban group and 102 patients (mean age 66.7±8.6 years; 78 men) to the clopidogrel group. The primary safety endpoint was bleeding as classified by the TIMI (Thrombolysis in Myocardial Infarction) criteria and ISTH (International Society of Thrombosis and Hemostasis) criteria; the efficacy endpoint was the rate of restenosis/reocclusion. RESULTS: There were no major or life-threatening bleeding events in the edoxaban group, while there were 2 major and 2 life-threatening bleeding events in the clopidogrel group by the TIMI criteria. By the ISTH classification, there was 1 major and 1 life-threatening bleeding event vs 5 major and 2 life-threatening bleeding events, respectively [relative risk (RR) 0.20, 95% confidence interval (CI) 0.02 to 1.70]. The bleeding risk was not statistically different with either treatment when assessed by TIMI or ISTH. Following 6 months of observation, there was a lower incidence of restenosis/reocclusion with edoxaban compared with clopidogrel (30.9% vs 34.7%; RR 0.89, 95% CI 0.59 to 1.34, p=0.643). CONCLUSION: These results suggest that patients who have undergone EVT have similar risks for major and life-threatening bleeding events with edoxaban and aspirin compared with clopidogrel and aspirin. The incidence of restenosis/reocclusion events, while not statistically different, was lower with edoxaban and aspirin, but an adequately sized trial will be needed to confirm these findings.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Moll F, Baumgartner I, Jaff M, et al. Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial. J Endovasc Ther. 2018. PMID: 29552984. doi:10.1177/1526602818760488

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。